Comparative analysis of autologous chondrocyte implantation and other treatment modalities: a systematic review

Naveen, Sangeetha Vasudevaraj; Robson, Noorzurani; Kamarul, Tunku

doi:10.1007/s00590-011-0798-6

Cited by 7 publications

(11 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is especially true for articular cartilage, which is an avascular tissue with limited access to progenitor cells which could drive repair of damaged tissue. Though the use of autologous chondrocytes for treating focal cartilage defects has been demonstrated, and compared favorably to other treatment methods including microfracture and mosaicplasty, the procedure is far from ideal. Harvesting chondrocytes from a biopsy of a patient's own cartilage causes donor site morbidity .…”

Section: Introductionmentioning

confidence: 99%

Engineered Microtissues Formed by Schiff Base Crosslinking Restore the Chondrogenic Potential of Aged Mesenchymal Stem Cells

Millan

Cavalli

Groth

et al. 2015

Adv Healthcare Materials

View full text Add to dashboard Cite

A universal method for reproducibly directing stem cell differentiation remains a major challenge for clinical applications involving cell-based therapies. The standard approach for chondrogenic induction by micromass pellet culture is highly susceptible to interdonor variability. A novel method for the fabrication of condensation-like engineered microtissues (EMTs) that utilizes hydrophilic polysaccharides to induce cell aggregation is reported here. Chondrogenesis of mesenchymal stem cells (MSCs) in EMTs is significantly enhanced compared to micromass pellets made by centrifugation measured by type II collagen gene expression, dimethylmethylene blue assay, and histology. MSCs from aged donors that fail to differentiate in pellet culture are successfully induced to synthesize cartilage-specific matrix in EMTs under identical media conditions. Furthermore, the EMT polysaccharides support the loading and release of the chondroinduction factor transforming growth factor β3 (TGF-β3). TGF-β-loaded EMTs (EMT(+TGF) ) facilitate cartilaginous tissue formation during culture in media not supplemented with the growth factor. The clinical potential of this approach is demonstrated in an explant defect model where EMT(+TGF) from aged MSCs synthesize de novo tissue containing sulfated glycosaminoglycans and type II collagen in situ.

show abstract

Section: Introductionmentioning

confidence: 99%

Engineered Microtissues Formed by Schiff Base Crosslinking Restore the Chondrogenic Potential of Aged Mesenchymal Stem Cells

Millan

Cavalli

Groth

et al. 2015

Adv Healthcare Materials

View full text Add to dashboard Cite

show abstract

“…This was similar to that reported in most other studies. 4,5,11,12,14,[17][18][19] Despite this, it is to be expected that certain studies would be more preferred owing to the robust study design employed. A study which is of a clinical trial in nature involving comparative or control groups will provide more convincing results especially when this study involves large numbers of cohorts.…”

Section: Discussionmentioning

confidence: 99%

Advances of human bone marrow-derived mesenchymal stem cells in the treatment of cartilage defects: A systematic review

Gopal

Amirhamed

Kamarul

2014

Exp Biol Med (Maywood)

Self Cite

View full text Add to dashboard Cite

Mesenchymal stem cell (MSC)-based therapies represent a new option for treating damaged cartilage. However, the outcomes following its clinical application have seldom been previously compared. The present paper presents the systematic review of current literatures on MSC-based therapy for cartilage repair in clinical applications. Ovid, Scopus, PubMed, ISI Web of Knowledge and Google Scholar online databases were searched using several keywords, which include "cartilage" and "stem cells". Only studies using bone marrow-derived MSC (BM-MSC) to treat cartilage defects clinically were included in this review. The clinical outcomes were compared, and the quality of the tissue repair was analysed where possible. Of the 996 articles, only six (n = 6) clinical studies have described the use of BM-MSC in clinical applications. Two studies were cohort observational trials, three were case series, and one was a case report. In the two comparative trials, BM-MSCs produced superior repair to cartilage treatment without cells and have comparable outcomes to autologous chondrocyte implantation. The case series and case-control studies have demonstrated that use of BM-MSCs resulted in better short- to long-term clinical outcomes with minimal complications. In addition, histological analyses in two studies have resulted in good repair tissue formation at the damaged site, composed mainly of hyaline-like cartilage. Although results of the respective studies are highly indicative that BM-MSC-based therapy is superior, due to the differences in methods and selection criteria used, it was not possible to make direct comparison between the studies. In conclusion, published studies do suggest that BM-MSCs could provide superior cartilage repair. However, due to limited number of reports, more robust studies might be required before a definitive conclusion can be drawn.

show abstract

“…19 Both ACI and MACI have been found to be superior to microfracture for the treatment of larger articular defects. 20,21 However, the current standard for treatment of severe joint injuries and advanced OA still involves partial or total joint replacements.…”

Section: Tissue Engineering Applications In Oamentioning

confidence: 99%

Immune Modulation to Improve Tissue Engineering Outcomes for Cartilage Repair in the Osteoarthritic Joint

Fahy

Farrell

Ritter

et al. 2015

Tissue Engineering Part B: Reviews

View full text Add to dashboard Cite

Comparative analysis of autologous chondrocyte implantation and other treatment modalities: a systematic review

Cited by 7 publications

References 24 publications

Engineered Microtissues Formed by Schiff Base Crosslinking Restore the Chondrogenic Potential of Aged Mesenchymal Stem Cells

Engineered Microtissues Formed by Schiff Base Crosslinking Restore the Chondrogenic Potential of Aged Mesenchymal Stem Cells

Advances of human bone marrow-derived mesenchymal stem cells in the treatment of cartilage defects: A systematic review

Immune Modulation to Improve Tissue Engineering Outcomes for Cartilage Repair in the Osteoarthritic Joint

Contact Info

Product

Resources

About